Eligo Bioscience

Startup

Summarized by Halo AI

Eligo Bioscience is a leader in in vivo microbiome gene editing. It develops precision genetic medicines using a proprietary platform to modulate bacterial DNA in the gut to treat diseases in immuno-inflammation, oncology, and infectious areas.

Founded & HQ

Paris, France

Company size

11-50 employees

Funding

~$58.7M

IP status

100 patents filed · 3 grants confirmed

Activity highlights

Secured a $5 million grant from the French government to accelerate and scale up its topical gene delivery platform for immuno-dermatology.

Eligo Bioscience (founded 2014) is a microbiome biotech company building “eligobiotics” – CRISPR-carrying phages to precisely edit or eliminate bacteria. Initially focusing on medical applications (like treating gut infections), it exemplifies the broader potential of CRISPR phage technology.

AI summary generated on Jun 22, 2026

OpenAlex

For general inquiries

Xavier Duportet

Cofounder & CEO

Is this page yours? Boost its visibility

List technologies, facilities, services, or grant collaboration opportunities.

Eligo Bioscience

For general inquiries

Key links